Medarex Announces Presentations on UltiMAb(R) Antibodies at 71st Annual Meeting of the American College of Rheumatology
Thursday November 8, 7:00 am ET
PRINCETON, N.J., Nov. 8 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX - News) announced today that at least five antibodies generated from Medarex's UltiMAb® technology in which Medarex wholly owns or has an economic interest through co-promote/profit sharing rights, royalties and/or equity ownership, are expected to be the subject of oral or poster presentations at the 71st Annual Meeting of the American College of Rheumatology (ACR), being held November 6-11, 2007 in Boston.
Golimumab (CNTO 148) and ustekinumab (CNTO 1275) Phase III or Phase II clinical data for inflammatory diseases in development by Medarex's licensing partner, Centocor, Inc.
-- "Golimumab, a new, human TNF-alpha antibody administered as a monthly subcutaneous injection in ankylosing spondylitis (AS): 24-week efficacy and safety results of the randomized, placebo-controlled GO-RAISE study" (Presentation #L10, Spondylarthropathies and Psoriatic Arthritis Session) - Poster presentation scheduled for Thursday, November 8, 2007 at 8:00 A.M.
-- "Characterization of golimumab (CNTO 148), a novel monoclonal antibody specific for human TNFa" (Presentation #274, RA Treatment: Small Molecules Sessions) - Poster presentation scheduled for Thursday, November 8, 2007 at 8:00 A.M.
-- "Phase II, randomized, placebo-controlled study of CNTO 1275, a human interleukin-12/23 monoclonal antibody, in psoriatic arthritis" (Presentation #L16, Spondylarthropathies and Psoriatic Arthritis Session) - Oral presentation scheduled for Saturday, November 10, 2007 at 3:15 P.M.
-- "Golimumab, a new human TNF-alpha antibody administered as a monthly subcutaneous injection in psoriatic arthritis: 24-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study" (Presentation #L14, Spondylarthropathies and Psoriatic Arthritis Session) - Oral presentation scheduled for Saturday, November 10, 2007 at 2:45 P.M.
On November 1, 2007, Johnson & Johnson announced that it will sponsor an analyst meeting and webcast on Thursday, November 8, 2007, from 5:00-6:00 P.M. Eastern Time to discuss late-stage compounds, including golimumab and ustekinumab.
Ofatumumab (HuMax-CD20) Phase II clinical data for rheumatoid arthritis in development by Medarex's licensing partner, Genmab A/S
-- "Ofatumumab, a human CD20 monoclonal antibody, in the treatment of rheumatoid arthritis: early results from an ongoing, double-blind, randomized, placebo controlled clinical trial" (Presentation #2086, RA Treatment: Small Molecules Session) - Poster presentation scheduled for Saturday, November 10, 2007 at 3:00 P.M.
MEDI-545 Phase I clinical data for systemic lupus erythematosus in development by Medarex's partner, MedImmune, Inc.
-- "Safety of MEDI-545, an anti-interferon-. monoclonal antibody, in MI-CP126, a phase I study in systemic lupus erythematosus (SLE)"(Presentation #428, SLE Session) - Poster presentation scheduled for Thursday, November 8, 2007 at 8:00 A.M.
-- "Neutralization of type I IFN inducible genes in phase I trial of anti-IFNa mAb for the treatment of SLE: utility as pharmacodynamic markers" (Presentation #429, SLE Session) - Poster presentation scheduled for Thursday, November 8, 2007 at 8:00 A.M.
-- "Anti-IFN-a antibody neutralization of early and late transcriptional responses in PBMC stimulated with serum from SLE patients" (Presentation #840, Genetics, Genomics and Proteomics Session) - Poster presentation scheduled for Friday, November 9, 2007 at 8:00 A.M.
-- "MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus" (Presentation #1315, SLE Session) - Oral presentation scheduled for Friday, November 9, 2007 at 2:30 P.M.
Preclinical data for an anti-CD70 antibody in development by Medarex
-- "Functional blocking and targeted depletion of activated lymphocytes by fucosylated and non-fucosylated fully human anti-CD70 IgG1" (Presentation #1984, T-cell Biology and Targets in Autoimmune Disease Session) - Poster presentation scheduled for Saturday, November 10, 2007 at 8:00 A.M. |
